Understanding Protein Regulation in Cells
Significance of Protein Research
Scientists are exploring how cells manage the proteins located on their membranes. This research is pivotal, as it may lead to breakthroughs in developing treatments for Alzheimer’s disease. Proteins, which are complex molecules, are essential for various cellular functions. They consist of amino acid chains that fold into distinct three-dimensional structures, each tailored for specific roles. Much like tools with specialized shapes, proteins are designed to execute distinct tasks.
Impact of Misfolded Proteins
Proteins are synthesized within cells, but sometimes they misfold or suffer damage due to environmental stresses, including high temperatures and oxidative stress. Such abnormalities can lead to protein aggregation, which can harm the cell. These misfolded proteins are linked to various protein deposition diseases, including Alzheimer’s, Huntington’s, and Parkinson’s diseases. In Alzheimer’s, for instance, beta-amyloid peptides become toxic as they aggregate and form plaques outside the cell.
Protein Quality Control Mechanisms
Chaperones and Their Role
Healthy cells implement protein quality control systems to ensure proper protein folding. Chaperones, specialized proteins, play a crucial role in this process by either refolding misfolded proteins using energy (ATP) or marking them for degradation.
Challenges for Secreted Proteins
Not all proteins function within the cell; some are secreted and can be vulnerable to damage from various stressors, including pathological conditions and pH imbalances. The fate of these proteins when they undergo structural changes is a critical area of study. Certain chaperone proteins, such as clusterin, are secreted but face challenges due to the lower ATP availability outside the cell, hindering their ability to refold misfolded proteins.
Investigating Clusterin Functionality
Research Objectives
A team of scientists from Japan recently published findings in the Journal of Cell Biology, focusing on how clusterin operates. They hypothesized that clusterin binds to misfolded proteins and facilitates their internalization by cells for degradation.
New Internalization Test
To investigate this, the researchers developed a novel internalization test to determine if clusterin-bound misfolded proteins could enter cells and be degraded in lysosomes, which are responsible for protein breakdown in acidic environments. By genetically engineering clusterin to include two fluorescent proteins, they could track the internalization and degradation processes.
Experimental Findings
Combining their internalization assay with flow cytometry and fluorescence microscopy, the scientists demonstrated that the clusterin-misfolded protein complex was preferentially internalized and degraded via lysosomes. This internalization was consistent across various cell types, including kidney, ovary, lung, bone, liver, and colon cells. Notably, they confirmed that beta-amyloid peptides could bind to clusterin and be degraded in human embryonic kidney cells.
Identifying the Clusterin Receptor
Exploring Cell Surface Receptors
The researchers aimed to identify a receptor on the cell surface that binds clusterin and initiates the internalization process. Using a genome-wide CRISPR screen, they identified 20 genes crucial for clusterin uptake, many of which were linked to heparan sulfate (HS) synthesis.
Testing the Heparan Sulfate Pathway
To ascertain if HS acted as the receptor for clusterin, the team genetically modified cells to prevent the expression of genes involved in the HS pathway. They discovered that knocking out these genes resulted in decreased internalization of the clusterin-misfolded protein complex. Restoring gene expression reversed this effect, indicating that disruption of the HS pathway specifically impeded the uptake of the clusterin complex.
Novel Mechanism Discovery
Through a pull-down assay, the team confirmed that clusterin binds directly to HS, suggesting it serves as the receptor for the uptake of clusterin-misfolded protein complexes. They further established that HS acted as the receptor regardless of the specific misfolded proteins involved, including beta-amyloid peptides.
Implications for Alzheimer’s Disease Research
Introducing the CRED Pathway
This research unveiled a novel mechanism for regulating extracellular proteins, termed the chaperone- and receptor-mediated extracellular protein degradation (CRED) pathway. While this discovery is promising, further investigation is necessary to understand its relevance to Alzheimer’s disease. The current tests involving beta-amyloid peptides were conducted in kidney cells, not neuronal cell lines, and the mechanism’s efficacy in animal models remains unexplored.
Future Considerations
It is worth noting that merely increasing clusterin expression may not lead to effective Alzheimer’s treatments, as its overexpression has been linked to cancer pathogenesis. Nonetheless, the findings contribute significantly to our foundational understanding of protein regulation outside cells and hold potential for addressing various protein deposition diseases.
Conclusion
This research represents an exciting advancement in understanding protein regulation in extracellular environments, paving the way for future studies on Alzheimer’s disease and related conditions.
References
1. Yerbury, J. J., Stewart, E. M., Wyatt, A. R. & Wilson, M. R. Quality control of protein folding in extracellular space. EMBO reports 6, 1131-1136 (2005).
2. Jones, S. E. & Jomary, C. Clusterin. The international journal of biochemistry & cell biology 34, 427-431 (2002).
3. Nuutinen, T., Suuronen, T., Kauppinen, A. & Salminen, A. Clusterin: a forgotten player in Alzheimer’s disease. Brain research reviews 61, 89-104 (2009).
4. Wyatt, A. R., Yerbury, J. J., Ecroyd, H. & Wilson, M. R. Extracellular chaperones and proteostasis. Annual review of biochemistry 82, 295-322 (2013).
5. Itakura, E., Chiba, M., Murata, T. & Matsuura, A. Heparan sulfate is a clearance receptor for aberrant extracellular proteins. Journal of Cell Biology 219 (2020).